The treatment combination was previously approved in BRCA2m-positive patients with metastatic castrate-resistant prostate cancer.
CSPC Pharmaceutical Group ( ($HK:1093) ) just unveiled an announcement. CSPC Pharmaceutical Group has received marketing approval from China’s ...
CSPC is one of the largest and oldest pharmaceutical companies in China. Anchored by its nervous system business segment due to its flagship drug NBP, CSPC has a portfolio of innovative and generic ...
CSPC Pharmaceutical Group ( ($HK:1093) ) has shared an announcement. CSPC Pharmaceutical Group announced that its subsidiary, CSPC Innovation ...
Jefferies analyst Chris Lui maintained a Buy rating on CSPC Pharmaceutical Group (CHJTF – Research Report) yesterday and set a price target of HK$8.20. Chris Lui has given a Buy rating to CSPC ...
AstraZeneca has returned to recent licensing partner CSPC Pharmaceutical with $110 million in upfront cash to start work on finding new oral drugs for a range of chronic diseases. The Friday morning ...
Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter ...
Investing.com -- CSPC Pharmaceutical has received approval from the U.S. Food and Drug Administration to conduct clinical trials for its recombinant fully human anti-ActRIIA/IIB monoclonal antibody ...
Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks CSPC Pharmaceutical Group has ...
AstraZeneca is paying CSPC Pharmaceutical Group $110 million up front to tap that China-based biotech’s artificial intelligence-driven technology for discovering and developing novel oral drugs. The R ...
Explore the HK:1093 financials. Find the CSPC Pharma financial statements for a comprehensive overview of the company’s financial health. This summary highlights critical numbers from key financial ...
FILE PHOTO: Moderna's COVID-19 vaccine at the McKesson distribution center in Olive Branch, Mississippi FILE PHOTO: Moderna's COVID-19 vaccine at the McKesson distribution center in Olive Branch, ...